<DOC>
	<DOCNO>NCT00240006</DOCNO>
	<brief_summary>To compare effectiveness 90-day Copaxone® adherence enhancement program sample MS patient high risk nonadherence receive support Shared Solutions® MS Center versus receive support Shared Solutions® .</brief_summary>
	<brief_title>A Study Comparing Shared Solutions® Plus MS Center Support Versus Shared Solutions® Alone</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Males female , 18 year age old . 2 . Diagnosed Relapsing Remitting Multiple Sclerosis ( relapse accept ) . 3 . Beginning restart therapy Glatiramer Acetate ( Copaxone® ) . 4 . Willing able complete procedure evaluation relate study . 5 . Willing provide inform consent . 1 . Taking immunomodulatory immunosuppressant therapy conjunction Copaxone® . 2 . Has significant medical illness MS may interfere assessment endpoint subject 's participation trial full duration study . 3 . Any situation investigator nurse ( investigator ) feel may interfere participation study . 4 . Pregnant try become pregnant , breast feeding study . 5 . Previously participate study another clinical research study past 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Copaxone®</keyword>
	<keyword>Shared Solutions®</keyword>
</DOC>